Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.

ABSTRACT:

Background

Beta-blocker therapies for cardiovascular comorbidities are often withheld in patients with chronic obstructive pulmonary disease (COPD) due to potential adverse effects on airway obstruction. We carried out a post hoc analysis to determine the efficacy and safety of aclidinium in patients with moderate-to-very severe COPD and increased cardiovascular risk receiving beta-blockers at baseline versus non-users.

Methods

ASCENT-COPD was a Phase 4, multicenter, double-blind, randomized, placebo-controlled, parallel-group study. Patients were randomized 1:1 to aclidinium or placebo twice-daily for up to 3 years. Outcomes included risk of (time to first) major adverse cardiovascular events (MACE), all-cause mortality, and lung function over 3 years, and exacerbations ove

SUBMITTER: Chapman KR 

PROVIDER: S-EPMC8532273 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature